Semaglutide significantly improved physical quality of life in adults with schizophrenia and obesity over 30 weeks, with about half the effect potentially mediated through weight loss.
PCS improvement exceeds minimally important differenceSemaglutide produced clinically meaningful improvements in physical quality of life at both 15 and 30 weeks in adults with schizophrenia and obesity.
What the researchers found
Semaglutide improved Physical Component Summary (PCS) scores at both weeks 15 and 30, with effect sizes exceeding the minimally important difference. Causal mediation analysis estimated that approximately half of the total PCS improvement at week 30 was mediated through weight change, though indirect effects did not reach statistical significance individually.
No significant effects were found for Mental Component Summary (MCS) scores or PANSS-6 psychiatric symptom scores. This suggests semaglutide's benefits in schizophrenia are primarily physical rather than psychological, at least over 30 weeks.
Why it matters
Antipsychotic-induced weight gain is one of the most burdensome side effects of schizophrenia treatment, contributing to metabolic disease and reduced quality of life. Showing that semaglutide — a GLP-1 peptide drug — can meaningfully improve physical quality of life in this vulnerable population provides evidence for its use beyond general obesity, addressing a significant unmet medical need.
How the study worked
Secondary analysis of a randomized, double-blind, placebo-controlled trial. 154 adults with schizophrenia spectrum disorder, prediabetes, and overweight/obesity were randomized 1:1 to once-weekly semaglutide or placebo for 30 weeks. Outcomes included SF-36v2 Physical and Mental Component Summary scores and PANSS-6 psychiatric symptoms. Causal mediation analyses estimated direct and indirect (via weight loss) effects at weeks 15 and 30.
What this study cannot tell us
The 30-week duration may be too short to detect mental health quality of life improvements, which the authors acknowledge. The study enrolled only patients with prediabetes and overweight/obesity, so results may not apply to all schizophrenia patients. The mediation through weight loss, while estimated at ~50%, was not statistically significant, limiting causal conclusions. This was a secondary analysis of a trial designed with different primary endpoints.
How to read the evidence
This is a secondary analysis from a well-designed randomized, double-blind, placebo-controlled trial with 154 participants. While the trial design is strong, the quality of life outcomes were secondary endpoints, and the mediation analysis has inherent statistical limitations.
When this study was published
Published in 2026, this is among the most current evidence on GLP-1 agonist use in psychiatric populations, addressing a rapidly growing area of clinical interest.
The bigger picture
GLP-1 receptor agonists are being explored across an expanding range of conditions beyond diabetes and obesity. This trial adds schizophrenia to the list of populations that may benefit, addressing the metabolic consequences of antipsychotic medications. As evidence accumulates that GLP-1 peptide drugs improve quality of life in diverse patient groups, they may become a standard adjunct to antipsychotic therapy for patients with metabolic complications.
Questions still open
- Would longer semaglutide treatment eventually improve mental quality of life or psychiatric symptoms in schizophrenia?
- Is the physical quality of life improvement driven by weight loss alone, or does semaglutide have independent effects on physical functioning?
- How do the benefits compare to structured lifestyle interventions for weight management in schizophrenia?
Common questions
Why do people with schizophrenia often struggle with weight gain?
Did semaglutide help with psychiatric symptoms of schizophrenia?
Read the original research
Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.
Schizophrenia research, 291, 20-26
Citation
Uhrenholt, N; Ganeshalingam, A; Arnfred, S; Gæde, P; Pedersen, A K; Larsen, P V; Frystyk, J; Bilenberg, N. (2026). Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.. Schizophrenia research, 291, 20-26. https://doi.org/10.1016/j.schres.2026.02.009